Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

75.16 -0.94 (-1.24%)
Delayed Quote Updated: 12:41 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year ↗
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% ↗
10x Genomics provides advanced tools for single cell and spatial biology research, serving academic and biopharma institutions worldwide. 
Via The Motley Fool
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Question
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
10x Genomics (NASDAQ:TXG) Beats Q1 Estimates But Falls as Revenue Shrinks Year-Over-Year ↗
Via Chartmill
10X Genomics (NASDAQ:TXG) Posts Q4 Earnings Beat Amid Cautious 2026 Outlook ↗
Via Chartmill
Topics Earnings
News headline image
10x Genomics Q1 Earnings Call Highlights ↗
10x Genomics (NASDAQ:TXG) reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument... 
Via MarketBeat
Topics Earnings
News headline image
Why 10x Genomics (TXG) Stock Is Down Today
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter results, although beating expec... 
Via StockStory
News headline image
TXG Q1 Deep Dive: Atara Launch, Spatial Platform Transition, and AI-Driven Demand
Biotech company 10x Genomics (NASDAQ:TXG) announced better-than-expected revenue in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 million. The com... 
Via StockStory
News headline image
10x Genomics (TXG) Q1 2026 Earnings Transcript ↗
10x Genomics (TXG) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
10x Genomics’s (NASDAQ:TXG) Q1 CY2026: Beats On Revenue But Stock Drops
Biotech company 10x Genomics (NASDAQ:TXG) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 mi... 
Via StockStory
News headline image
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results this Thursday after the bell. Here’s what to look for. 10x Genomics beat analys... 
Via StockStory
News headline image
1 Unprofitable Stock to Target This Week and 2 That Underwhelm
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Ignore
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
Why 10x Genomics (TXG) Shares Are Trading Lower Today
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.4% in the afternoon session after a key industry peer, Thermo Fisher Scientific (TM... 
Via StockStory
Topics Artificial Intelligence Government Stocks
News headline image
3 Overrated Stocks We Keep Off Our Radar
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
Via StockStory
Topics Economy
News headline image
3 Small-Cap Stocks We Steer Clear Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Economy Government Stocks
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The widely followed investor has been buying stocks trading well below their all-time highs. 
Via The Motley Fool
News headline image
These Are the Only 3 Stocks That Cathie Wood Bought Last Week ↗
The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
3 Reasons to Sell TXG and 1 Stock to Buy Instead
10x Genomics has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 39.8% and now trades at $18.24. This... 
Via StockStory
Topics Stocks Supply Chain
News headline image
1 Cash-Producing Stock with Competitive Advantages and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
3 Russell 2000 Stocks We Approach with Caution
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
Topics Retirement
News headline image
Life Sciences Tools & Services Stocks Q4 In Review: 10x Genomics (NASDAQ:TXG) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the life sciences tools & services stocks, including 10x Genomics (NASDAQ:TXG) and its ... 
Via StockStory
Topics Artificial Intelligence
News headline image
The "Flight to Quality": Thermo Fisher’s Q4 Beat and Dividend Hike Cement Defensive Leadership for 2026
WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the... 
Via MarketMinute
Topics Earnings Economy World Trade
News headline image
3 Stocks Under $50 We’re Skeptical Of
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Topics Artificial Intelligence
News headline image
5 Must-Read Analyst Questions From 10x Genomics’s Q4 Earnings Call
10x Genomics’ fourth quarter results saw stable revenue performance despite a subdued research funding environment, with management crediting continued consumables growth and increased adoption of new... 
Via StockStory
Topics Earnings
News headline image
3 Volatile Stocks We Steer Clear Of
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
News headline image
Why Is 10x Genomics (TXG) Stock Soaring Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 10.5% in the morning session after the company reported better-than-expected fourth-quarter results, highlighted by a smaller loss than... 
Via StockStory
Topics Government World Trade
News headline image
TXG Q4 Deep Dive: Consumables Growth, Spatial Expansion, and AI-Driven Demand Shape Outlook
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $166 million. The company expects the full year’s... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.